Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 15/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15728454 | 0.89 | FGFR3 (0.59) | WEE1FGFR4FGFR3FGFR1FGFR2 | |
| SCHEMBL15709766 | 0.88 | FGFR3 (0.56) | FGFR4FGFR3FGFR1FGFR2KCNH2 | |
| SCHEMBL18132689 | 0.83 | FGFR3 (0.51) | FGFR4FGFR3FGFR1FGFR2KCNH2 | |
| SCHEMBL15244057 | 0.82 | IGF1R (0.53) | FGFR4FGFR3FGFR1FGFR2KCNH2 | |
| SCHEMBL15728666 | 0.81 | FGFR3 (0.64) | WEE1FGFR4FGFR3FGFR1FGFR2 | |
| SCHEMBL15728440 | 0.79 | FGFR3 (0.68) | FGFR4FGFR3FGFR1FGFR2KCNH2 | |
| SCHEMBL15709931 | 0.79 | FGFR3 (0.55) | FGFR4FGFR3FGFR1FGFR2KCNH2 | |
| SCHEMBL15728668 | 0.77 | KCNH2 (0.60) | FGFR4FGFR3FGFR1FGFR2KCNH2 | |
| SCHEMBL18132625 | 0.77 | IGF1R (0.50) | FGFR4FGFR3FGFR1FGFR2KCNH2 | |
| SCHEMBL15709889 | 0.77 | FGFR3 (0.57) | FGFR4FGFR3FGFR1FGFR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | WEE1 896/4885FGFR4 4/4885FGFR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.